Chiara Dalle Fratte^*, Silvia Mezzalira^*, Jerry Polesel^†, Elena De Mattia^*, Antonio Palumbo^‡, Angela Buonadonna^§, Elisa Palazzari^¶, Antonino De Paoli^¶, Claudio Belluco^#, Vincenzo Canzonieri^‡** , Giuseppe Toffoli^*, Erika Cecchin^*

Oncology Research, Vol.28, No.9, pp. 847-855, 2020, DOI:10.3727/096504021X16232280278813

Abstract Pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients is related to a favorable prognosis. The identification of early biomarkers predictive of pathological complete response would help optimize the multimodality management of the patients. A panel of 11 tumor-related proteins was investigated by immunohistochemistry in the pretreatment biopsy of a group of locally advanced rectal cancer patients to identify early biomarkers of pathological complete response to neoadjuvant chemoradiotherapy. A mono-institutional retrospective cohort of 95 stage II/III locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy and surgery was selected based on clinical–pathological characteristics and the availability of… More >

Xiaodan He, Jingshi Wang, Zhao Wang^*

Oncologie, Vol.23, No.4, pp. 559-567, 2021, DOI:10.32604/oncologie.2021.018647

Abstract Despite extensive work-ups, some patients have been diagnosed with hemophagocytic lymphohistiocytosis (HLH) of unknown etiology. For HLH of unknown etiology, to investigate the clinical features and the factors that may affect the prognosis, we retrospectively reviewed the medical records of 94 patients hospitalized from January 2014 to December 2019. Survival times were evaluated until April 2020. For the 94 patients, the underlying causes of their diseases remained unclear at the end of the follow-up period, and the 1-, 3-, and 6-month survival rates, and the overall survival (OS) rates were 86.2%, 78.7%, 73.4%, and 70.2%, respectively. The multivariate analysis showed… More >